# A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

> **NCT07024407** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ashibio Inc** · enrollment: 10 (estimated)

## Conditions studied

- Heterotopic Ossification (HO)

## Interventions

- **DRUG:** Andecaliximab

## Key facts

- **NCT ID:** NCT07024407
- **Lead sponsor:** Ashibio Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-14
- **Primary completion:** 2025-12
- **Final completion:** 2026-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024407, "A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07024407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*